Riskpilot← Back to searchSign inGet full accessArteLux AB
ABActiveOrg 5592097884Frejagatan 21Medical specialists activities · NACE 8622Est. 20192 employees
Revenue 2025
SEK 3,1M
-24% vs 2024
EBITDA margin
39.2%
-44% vs 2024
Equity ratio
31.5%
Financial strength
Net profit 2025
SEK 510K
-53% vs 2024
| Revenue | SEK 3,1M | -24% |
| EBITDA | SEK 1,2M | -44% |
| Net profit | SEK 510K | -53% |
| Total assets | SEK 5,8M | +1% |
| Equity | SEK 1,8M | -16% |
| Employees | 2 | — |
Legal name
ArteLux AB
Org number
5592097884
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
20 juni 2019
Share capital
SEK 50 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-05-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Företaget ska bedriva hälso- och sjukvård, friskvård, utbildning, medicinska konsulttjänster, handel med friskvårdsoch sjukvårdsartiklar, samt därmed förenlig verksamhet.
Address
Frejagatan 21
Email
dr.cima@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2 211 | 3 210 | 3 787 | 4 062 | 3 072 |
| Staff expenses | — | — | −2 061 | −1 635 | −1 632 |
| EBITDA | 1 303 | 1 362 | 1 400 | 2 135 | 1 205 |
| Depreciation & amort. | −0 | −0 | — | −125 | −125 |
| EBIT | 1 303 | 1 362 | 1 400 | 2 010 | 1 080 |
| Net financials | −1 | — | 6 | 56 | 38 |
| Profit before tax | 973 | 1 021 | 987 | 1 464 | 743 |
| Tax | −214 | −211 | −296 | −372 | −232 |
| Net profit | 759 | 810 | 691 | 1 093 | 510 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 806 | 3 152 | 3 713 | 5 689 | 5 769 |
| Equity | 1 008 | 1 635 | 1 712 | 2 160 | 1 820 |
| Long-term debt | 0 | 0 | — | 626 | 370 |
| Short-term debt | 450 | 648 | 472 | 473 | 457 |
| Total debt | 450 | 648 | 472 | 1 098 | 828 |
EBITDA margin
39.2%
This company
15.8%
Market median
+148% vs market
20212025
Equity ratio
31.5%
This company
38.2%
Market median
+18% vs market
20212025
Return on equity
28.0%
This company
18.4%
Market median
+52% vs market
20212025
Net profit margin
16.6%
This company
8.1%
Market median
+105% vs market
20212025
Asset turnover
0.53×
This company
1.12×
Market median
-53% vs market
20212025
Debt / equity
2.17×
This company
0.62×
Market median
-250% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-06-01 – 2025-05-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-06-01 – 2024-05-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-06-01 – 2023-05-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-06-01 – 2022-05-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-06-01 – 2021-05-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JR Audit | Audit | 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ArteLux AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jens Roland Brehme | Audit | 0 companies |
| Katarina Celovec Cima | Deputy Board Member | 0 companies |
| Ivan Cima | Board of Directors | 0 companies |